SEC Form 4 · accession 0001193125-26-255834
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nishant C Saxena
Officer — Chief Business Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 5:36 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001595097
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Jun 2, 2026 | P | 4,500 | $7.333 | A | 66,300 | D | |
| Common Stock, par value $0.0001 per shareF2 | Jun 3, 2026 | P | 9,000 | $7.58 | A | 75,300 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.33 to $7.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.